All In Biotech

Drug Trial Radar · NCT04676048

ASC618 Gene Therapy in Hemophilia A Patients

Assessment of Safety and Preliminary Efficacy of ASC618 in Subjects With Severe and Moderately Severe Hemophilia A

Last checked: Nov 19, 2026Latest source record: Feb 1, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Aug 3, 2022

Primary completion

Dec 2023

Study completion Dec 2026

Sponsor

Lead sponsor
ASC TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, encourage the current efforts for gene transfer therapy. This study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed promoter

Conditions

  • Hemophilia A

Interventions

  • ASC618Biological

    ASC618 will be given as a single IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of adverse events, and serious AEsTime frame: 12 months post-infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Arkansas Children's Hospital

    Little Rock, Arkansas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.